Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

BRISTOL DISCONTINUES ORAL d-SOTALOL SWORD TRIAL

  • News

Executive Summary

BRISTOL DISCONTINUES ORAL d-SOTALOL SWORD TRIAL on Nov. 1 because of increased mortality compared to placebo in patients taking the investigational class III (potassium channel blocking) anti-arrhythmic drug. The SWORD (Survival with Oral d-Sotalol) Data Safety Monitoring Committee examined interim data from 2,762 patients and determined that "the overall mortality in the d- sotalol group was 3.9% compared to 2% in the placebo group;" Bristol-Myers Squibb reported Nov. 4.

Table

View full table

Tags:
Latest Headlines

US FDA Inspectors, Product Centers Working Closer Together Ahead Of ORA Reorg

Not-For-Profit Models Needed For Commercially Unviable Rare Disease Drugs

EU Urban Wastewater Directive Update ‘Unfairly Targets Pharmaceutical Industry’

Swissmedic Gets New Grant For Regulatory Strengthening In LMICs

See All
UsernamePublicRestriction

Register

PS025249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By